About Samfara LLP
Samfara LLP is a London-based private equity firm focused on majority buyouts of lower-middle-market European life sciences companies. The firm pursues thesis-led investments in complex and international businesses, with an emphasis on active ownership and operational transformation. Its investment focus is the European life sciences sector, with geographic exposure across Europe. Samfara completed its first investment, the acquisition of Danish active pharmaceutical ingredient manufacturer Chr. Olesen Synthesis, in October 2026, backed by European and North American institutional investors and family offices. Samfara LLP was incorporated in 2023 and is headquartered in London, United Kingdom.